Abstract
Homologous recombination is almost the only way to modify the genome in a predetermined fashion, despite its quite low frequency in mammalian cells. It has been already reported that the frequency of this biological process can be notably increased by inducing a double strand break (DSB) at target site. This article presents completely chemistrybased artificial restriction DNA cutter (ARCUT) for the promotion of homologous recombination in human cells. This cutter is composed of Ce(IV)/EDTA complex (molecular scissors) and two strands of peptide nucleic acid (PNA), and contains no proteins. Its scission site in the genome is determined simply by Watson-Crick rule so that ARCUT for desired homologous recombination is easily and straightforwardly designed and synthesized. The site-specificity of the scission is high enough to cut human genome at one target site. The DSB induced by this cutter is satisfactorily recognized by the repair system in human cells and promotes the targeted homologous recombination.
Keywords: Genome manipulation, artificial restriction DNA cutter, cerium, peptide nucleic acid, homologous recombination, double strand break, phosphodiester, thymine, pcPNA strands, hypermethylation, X syndrome, fluorescent protein, green fluorescence, adenovirus vector
Current Gene Therapy
Title: Artificial Restriction DNA Cutters to Promote Homologous Recombination in Human Cells
Volume: 11 Issue: 1
Author(s): Hitoshi Katada and Makoto Komiyama
Affiliation:
Keywords: Genome manipulation, artificial restriction DNA cutter, cerium, peptide nucleic acid, homologous recombination, double strand break, phosphodiester, thymine, pcPNA strands, hypermethylation, X syndrome, fluorescent protein, green fluorescence, adenovirus vector
Abstract: Homologous recombination is almost the only way to modify the genome in a predetermined fashion, despite its quite low frequency in mammalian cells. It has been already reported that the frequency of this biological process can be notably increased by inducing a double strand break (DSB) at target site. This article presents completely chemistrybased artificial restriction DNA cutter (ARCUT) for the promotion of homologous recombination in human cells. This cutter is composed of Ce(IV)/EDTA complex (molecular scissors) and two strands of peptide nucleic acid (PNA), and contains no proteins. Its scission site in the genome is determined simply by Watson-Crick rule so that ARCUT for desired homologous recombination is easily and straightforwardly designed and synthesized. The site-specificity of the scission is high enough to cut human genome at one target site. The DSB induced by this cutter is satisfactorily recognized by the repair system in human cells and promotes the targeted homologous recombination.
Export Options
About this article
Cite this article as:
Katada Hitoshi and Komiyama Makoto, Artificial Restriction DNA Cutters to Promote Homologous Recombination in Human Cells, Current Gene Therapy 2011; 11 (1) . https://dx.doi.org/10.2174/156652311794520094
DOI https://dx.doi.org/10.2174/156652311794520094 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fenofibrate and Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Diet and Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Alternatives to Conventional Vaccines - Mediators of Innate Immunity
Current Drug Targets Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Modified LDL Immune Complexes and Cardiovascular Disease
Current Medicinal Chemistry Glucose Transporters in Sex Steroid Hormone Related Cancer
Current Vascular Pharmacology Evidence for Epigenetic Alterations in Turner Syndrome Opens up Feasibility of New Pharmaceutical Interventions
Current Pharmaceutical Design Future Developments in Osteoporosis Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Nutraceuticals, Nutritional Therapy, Phytonutrients, and Phytotherapy for Improvement of Human Health: A Perspective on Plant Biotechnology Application
Recent Patents on Biotechnology Oxidative Stress in Schizophrenia
Current Neuropharmacology Immunological Mechanism and Clinical Application of PAMP Adjuvants
Recent Patents on Anti-Cancer Drug Discovery Application of Genomic Resources and Gene Expression Profiles to Identify Genes That Regulate Bone Density
Current Genomics Potential Therapeutic Targets for Steroid-Resistant Asthma
Current Drug Targets The Quest for a Tumor Suppressor Gene Phenotype
Current Molecular Medicine Perioperative Considerations in Patients with Obstructive Sleep Apnea
Current Respiratory Medicine Reviews Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
Current Medicinal Chemistry Hashimotos Thyroiditis: From Genes to the Disease
Current Genomics Synthesis of Alkaloid Natural Products Using Solid-Supported Reagents and Scavengers
Current Organic Chemistry Seasonal and Perennial Allergic Conjunctivitis
Recent Patents on Inflammation & Allergy Drug Discovery Multiple-Target Drugs: Inhibitors of Heat Shock Protein 90 and of Histone Deacetylase
Current Drug Targets